Goldman Sachs Group Inc Macrogenics Inc Call Options Transaction History
Goldman Sachs Group Inc
- $580 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding MGNX
# of Institutions
150Shares Held
60.3MCall Options Held
218KPut Options Held
259K-
Bellevue Group Ag Kuesnacht, V89.94MShares$36.4 Million0.71% of portfolio
-
Armistice Capital, LLC New York, NY6MShares$22 Million0.33% of portfolio
-
Black Rock Inc. New York, NY5.4MShares$19.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.14MShares$15.1 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.31MShares$12.1 Million0.01% of portfolio
About MACROGENICS INC
- Ticker MGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,458,800
- Market Cap $225M
- Description
- MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...